Physician profile
Beth Respess
NPI 1710038682
$4,716.32
in general payments reported to CMS, 2019-2025
33 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $962 · 2023: $939 · 2024: $814 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,878 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,877.89 |
| Education | $164.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $527.00 | 2021-2025 | Jynarque |
| Ardelyx, INC. | $513.63 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $441.78 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals Lp | $349.10 | 2021-2024 | Farxiga, Lokelma |
| Amgen INC. | $340.00 | 2021-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $299.55 | 2021-2023 | Veltassa |
| Novartis Pharmaceuticals Corporation | $269.84 | 2021-2025 | |
| Travere Therapeutics, INC. | $268.59 | 2022-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $219.78 | 2021-2023 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $216.69 | 2021-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $178.17 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $139.08 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $134.54 | 2022-2024 | Velphoro |
| Xeris Pharmaceuticals, INC. | $93.45 | 2024-2025 | Keveyis |
| Ani Pharmaceuticals, INC. | $81.67 | 2023 | Purified Cortrophin Gel |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $81.21 | 2023-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.07 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $59.59 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $57.57 | 2021-2023 | Lupkynis |
| Lilly USA, LLC | $49.04 | 2021-2024 | Jardiance |
| Kyowa Kirin, INC. | $47.16 | 2023 | Crysvita |
| Takeda Pharmaceuticals U.S.A., INC. | $35.68 | 2023-2025 | Gattex |
| Abbvie INC. | $34.93 | 2021-2022 | |
| Amarin Pharma, INC. | $27.67 | 2021 | |
| Pfizer INC. | $27.36 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.26 | 2021 | |
| Boston Scientific Corporation | $20.33 | 2021 | |
| Ascendis Pharma Endocrinology INC | $20.08 | 2025 | Yorvipath |
| Genzyme Corporation | $19.81 | 2022 | |
| Exact Sciences Corporation | $19.29 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $18.16 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.26 | 2021 | |
| Daiichi Sankyo INC. | $15.98 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Respess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.